PT3366305T - Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos - Google Patents

Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos

Info

Publication number
PT3366305T
PT3366305T PT181536715T PT18153671T PT3366305T PT 3366305 T PT3366305 T PT 3366305T PT 181536715 T PT181536715 T PT 181536715T PT 18153671 T PT18153671 T PT 18153671T PT 3366305 T PT3366305 T PT 3366305T
Authority
PT
Portugal
Prior art keywords
methods
variable domains
single variable
immunoglobulin single
treating ttp
Prior art date
Application number
PT181536715T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PT3366305T publication Critical patent/PT3366305T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT181536715T 2014-06-16 2015-06-16 Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos PT3366305T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30

Publications (1)

Publication Number Publication Date
PT3366305T true PT3366305T (pt) 2020-12-21

Family

ID=51541255

Family Applications (5)

Application Number Title Priority Date Filing Date
PT181536715T PT3366305T (pt) 2014-06-16 2015-06-16 Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos
PT157298290T PT3154569T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536764T PT3332800T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt
PT181536749T PT3335724T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536731T PT3335723T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT157298290T PT3154569T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536764T PT3332800T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt
PT181536749T PT3335724T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536731T PT3335723T (pt) 2014-06-16 2015-06-16 Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt

Country Status (15)

Country Link
US (5) US10858445B2 (cg-RX-API-DMAC7.html)
EP (6) EP3335723B1 (cg-RX-API-DMAC7.html)
JP (3) JP6688746B2 (cg-RX-API-DMAC7.html)
KR (2) KR102568585B1 (cg-RX-API-DMAC7.html)
CN (1) CN106559985A (cg-RX-API-DMAC7.html)
AU (2) AU2015276237B2 (cg-RX-API-DMAC7.html)
CA (1) CA2952103A1 (cg-RX-API-DMAC7.html)
ES (5) ES2881331T3 (cg-RX-API-DMAC7.html)
IL (1) IL249540B (cg-RX-API-DMAC7.html)
NL (1) NL2013007B1 (cg-RX-API-DMAC7.html)
PL (5) PL3335723T3 (cg-RX-API-DMAC7.html)
PT (5) PT3366305T (cg-RX-API-DMAC7.html)
RU (1) RU2704444C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201811109PA (cg-RX-API-DMAC7.html)
WO (1) WO2015193326A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
CA3089211A1 (en) * 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
CA3201986A1 (en) * 2020-11-18 2022-05-27 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
EP4402165A1 (en) 2021-09-17 2024-07-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
US20240409666A1 (en) * 2021-12-10 2024-12-12 Renhao Li Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004037999A2 (en) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
CN100439400C (zh) 2003-01-10 2008-12-03 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
PT1836500E (pt) 2005-01-14 2010-09-28 Ablynx Nv Métodos e ensaios para distinguir diferentes formas de doenças e perturbações caracterizadas por trombocitopenia e/ou por interacção espontânea entre o factor de von willebrand (vwf) e plaquetas
BRPI0609797B8 (pt) * 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CN101977654A (zh) 2008-03-21 2011-02-16 埃博灵克斯股份有限公司 冯威勒布兰特因子特异性结合物及其应用方法
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
EP4116325A1 (en) * 2010-11-05 2023-01-11 Novartis AG Methods of treating rheumatoid arthritis using il-17 antagonists
MX350582B (es) 2011-06-10 2017-09-11 Baxalta Inc Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante.
KR102162413B1 (ko) 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CA3089211A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains

Also Published As

Publication number Publication date
KR102403388B1 (ko) 2022-06-03
CN106559985A (zh) 2017-04-05
RU2704444C2 (ru) 2019-10-28
PL3154569T3 (pl) 2021-11-02
EP3332800B1 (en) 2020-08-26
PL3335723T3 (pl) 2022-07-18
EP3332800A1 (en) 2018-06-13
CA2952103A1 (en) 2015-12-23
JP7105260B2 (ja) 2022-07-22
PL3332800T3 (pl) 2021-04-19
JP2017519762A (ja) 2017-07-20
RU2017100077A (ru) 2018-07-12
PT3332800T (pt) 2020-11-19
PL3366305T3 (pl) 2021-06-14
IL249540A0 (en) 2017-02-28
EP3366305B1 (en) 2020-11-18
AU2015276237B2 (en) 2021-02-25
EP3335723A1 (en) 2018-06-20
EP3335723B1 (en) 2022-03-30
EP3366305A1 (en) 2018-08-29
ES2881331T3 (es) 2021-11-29
PT3335724T (pt) 2022-08-02
IL249540B (en) 2021-09-30
US20170210822A1 (en) 2017-07-27
ES2915473T3 (es) 2022-06-22
AU2021202747A1 (en) 2021-05-27
KR20170015513A (ko) 2017-02-08
US20180155440A1 (en) 2018-06-07
JP2022160431A (ja) 2022-10-19
NL2013007B1 (en) 2016-07-05
AU2021202747B2 (en) 2024-02-15
US20180155442A1 (en) 2018-06-07
PT3335723T (pt) 2022-05-20
EP4059513A1 (en) 2022-09-21
EP3335724B1 (en) 2022-06-22
HK1256730A1 (en) 2019-10-04
AU2015276237A1 (en) 2017-01-19
PL3335724T3 (pl) 2022-09-19
KR20220053040A (ko) 2022-04-28
ES2924199T3 (es) 2022-10-05
EP3154569A1 (en) 2017-04-19
SG10201811109PA (en) 2019-01-30
JP6688746B2 (ja) 2020-04-28
RU2017100077A3 (cg-RX-API-DMAC7.html) 2018-12-25
HK1256731A1 (en) 2019-10-04
JP2020097600A (ja) 2020-06-25
EP3335724A1 (en) 2018-06-20
US12269893B2 (en) 2025-04-08
US10919980B2 (en) 2021-02-16
SG11201610488QA (en) 2017-01-27
US20180155441A1 (en) 2018-06-07
EP3154569B1 (en) 2021-04-21
ES2843642T3 (es) 2021-07-19
WO2015193326A1 (en) 2015-12-23
KR102568585B1 (ko) 2023-08-18
PT3154569T (pt) 2021-06-22
RU2019131713A (ru) 2019-11-11
ES2831865T3 (es) 2021-06-09
HK1258508A1 (en) 2019-11-15
US20180155443A1 (en) 2018-06-07
US10858445B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL257636A (en) Anti-tigit antibodies and methods of use
IL255278A0 (en) Anti-ox40 antibodies and methods of using them
ZA201606630B (en) Anti-ox40 antibodies and methods of use
SG10201912085WA (en) Anti-cd33 antibodies and methods of use thereof
IL244762A0 (en) Effective non-blocking resistors are based on vl variable domains and vhh based products
IL249540B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
IL272949A (en) Improved treatment of atopic dermatitis using tardifitant
IL265568A (en) Methods for treating TIM-3 elevation
HK1236434A1 (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof